Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Onyx

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Onyx's 2012 oncology sales performance.

Onyx Pharmaceuticals, Inc.

Eisai gets green light for Lenvima in kidney cancer

Eisai gets green light for Lenvima in kidney cancer Novartis' Votrient (pazopanib), Bayer/Onyx Nexavar (sorafenib), Pfizer's Sutent (sunitinib) or Roche's Avastin (bevacizumab).

Eisai's Lenvima gets FDA priority review for kidney cancer

Eisai's Lenvima gets FDA priority review for kidney cancer These include Novartis' Votrient (pazopanib), Bayer/Onyx Nexavar (sorafenib), Pfizer's Sutent (sunitinib) or Roche's Avastin (bevacizumab).

CRISPR Therapeutics appoints Dr Tony Coles

CRISPR Therapeutics appoints Dr Tony Coles Prior to founding Yumanity Dr Coles served as chairman and chief executive officer of Onyx Pharmaceuticals, which was acquired by Amgen in 2013 for $10.5bn.

FDA clears Takeda's oral multiple myeloma drug

FDA clears Takeda's oral multiple myeloma drug Approval of the orally-active drug gives myeloma patients an alternative to injectable proteasome inhibitors such as Takeda's own market-leading Velcade (bortezomib) and Amgen and Onyx' Kyprolis (carfilzomib), and ... Ninlaro also has a sizeable lead in

Pharma deals in September 2015

Pharma deals in September 2015 drug Kyprolis, acquired in the $10bn purchase of Onyx Pharmaceuticals.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...